<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124379</url>
  </required_header>
  <id_info>
    <org_study_id>21E1799/HC_001</org_study_id>
    <nct_id>NCT05124379</nct_id>
  </id_info>
  <brief_title>Hemoclin Gel for the Treatment of Hemorrhoids</brief_title>
  <official_title>Prospective, Open Clinical Investigation to Confirm the Effectiveness and Safety of Hemoclin Gel for the Treatment of Haemorrhoids.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karo Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karo Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post market, single arm, clinical investigation to assess safety and performance of the&#xD;
      product.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to asses the treatment of itch related to Haemorrhoids grade I or II.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Severity of itch will be evaluated by the patient with a 6 point structured scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate by the patient the efficacy of tested product on the severity of bleeding</measure>
    <time_frame>2 weeks</time_frame>
    <description>Wilcoxon signed rank test will be carried out to assess whether the median change from baseline is statistically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate by the patient the efficacy of tested product on the sense of discomfort</measure>
    <time_frame>2 weeks</time_frame>
    <description>Wilcoxon signed rank test will be carried out to assess whether the median change from baseline is statistically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the overall satisfaction of the patient according to</measure>
    <time_frame>2 weeks</time_frame>
    <description>Wilcoxon signed rank test will be carried out to assess whether the median change from baseline is statistically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the instant cooling effect, less painful toilet visit each day using a daily log,</measure>
    <time_frame>2 weeks</time_frame>
    <description>Wilcoxon signed rank test will be carried out to assess whether the median change from baseline is statistically significant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Hemorrhoids Grade I and II</condition>
  <arm_group>
    <arm_group_label>Hemoclin Gel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemoclin Gel</intervention_name>
    <description>Non sterile gel for intra-rectal use</description>
    <arm_group_label>Hemoclin Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy subjects.&#xD;
&#xD;
          2. Sex: male or female.&#xD;
&#xD;
          3. Age: more than 18 years old.&#xD;
&#xD;
          4. Symptomatic haemorrhoids stage 1 and 2 (Goligher classification).&#xD;
&#xD;
          5. Episodes of haemorrhoid-related itching experienced at least every other day during&#xD;
             the last two weeks before enrolment in the study.&#xD;
&#xD;
          6. Able to attempt bowel movements daily (defined as trying to have a bowel movement&#xD;
             while sitting on the toilet for at least a few minutes, at least once daily, whether&#xD;
             or not you feel the need to have a bowel movement that day).&#xD;
&#xD;
          7. Able and willing to provide informed consent and comply with study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing woman or planning a pregnancy during the study.&#xD;
&#xD;
          2. Subject not able or not willing to provide informed consent and comply with study&#xD;
             procedures&#xD;
&#xD;
          3. Subject who had been deprived of their freedom by administrative or legal decision.&#xD;
&#xD;
          4. Major subject who is under guardianship or who is not able to express his consent.&#xD;
&#xD;
          5. Subject in a social or sanitary establishment.&#xD;
&#xD;
          6. Subject suspected to be non-compliant according to the Investigator's judgment. In&#xD;
             terms of associated pathology&#xD;
&#xD;
          7. Grade III or IV haemorrhoids (Goligher classification).&#xD;
&#xD;
          8. Other pre-existing anal disorders and diseases including Crohns disease, ulcerative&#xD;
             colitis, undefined inflammatory bowel disease, anal fissures, perianal fistulas,&#xD;
             perianal rash or eczema, rectal prolapse, rectocele, benign or malignant anal and&#xD;
             rectal tumor and perianal infections.&#xD;
&#xD;
          9. Any anal surgery (including surgical or instrumental procedures in the last 60 days).&#xD;
             Relating to previous or ongoing treatment&#xD;
&#xD;
         10. Any anal topical medication applied in last 7 days.&#xD;
&#xD;
         11. Known or suspected sensitivity or allergy to ingredients of the investigational&#xD;
             product. In terms of COVID pandemic&#xD;
&#xD;
         12. Subject who was abroad in a country with higher incidence rate of Covid-19 than Poland&#xD;
             within 14 days before the beginning of the study.&#xD;
&#xD;
         13. Subject presenting following symptoms: cough, shortness of breath, elevated body&#xD;
             temperature - equal and above 37.5°C.&#xD;
&#xD;
         14. Subject who had contact with any person infected with COVID-19 within 10 days before&#xD;
             the beginning of the study.&#xD;
&#xD;
         15. Subject who is currently during home quarantine recommended by the Sanitary Inspection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diana Pasho</last_name>
    <phone>0031614706949</phone>
    <email>diana.pasho@karopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tomasz Nowak, Dr</last_name>
    <phone>0048 504263364</phone>
    <email>tomnowak@op.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GastroDent Gabinet Gastroenterologiczny z Pracownią Endoskopową&quot;</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Nowak, Dr</last_name>
      <phone>0048 504263364</phone>
      <email>tomnowak@op.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

